Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)
about
Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectorsDrugs for treating Buruli ulcer (Mycobacterium ulcerans disease)Current treatment of atypical mycobacteriosisNeglected tropical diseasesActivities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in miceRapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infectionAccelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans diseaseIn-vitro activity of avermectins against Mycobacterium ulceransNew anti-tuberculosis agents amongst known drugs.Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer.Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boostingFirst isolation of Mycobacterium ulcerans from an aquatic environment: the end of a 60-year search?Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial.Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).All-oral antibiotic treatment for buruli ulcer: a report of four patients.Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease.Use of fine-needle aspiration for diagnosis of Mycobacterium ulcerans infectionRapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.Laboratory confirmation of Buruli ulcer disease in Togo, 2007-2010.Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?Evaluation of the medicinal use of clay minerals as antibacterial agents.Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort studyIllness meanings and experiences for pre-ulcer and ulcer conditions of Buruli ulcer in the Ga-West and Ga-South Municipalities of Ghana.Detection of Mycobacterium ulcerans by the loop mediated isothermal amplification method.Contribution of the community health volunteers in the control of Buruli ulcer in Bénin.Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.Climate and landscape factors associated with Buruli ulcer incidence in Victoria, AustraliaTowards rational use of antibiotics for suspected secondary infections in Buruli ulcer patientsSurgical management of buruli ulcer disease: a four-year experience from four endemic districts in ghana.Genetic diversity of Staphylococcus aureus in Buruli ulcer.Clinical features and risk factors of oedematous Mycobacterium ulcerans lesions in an Australian population: beware cellulitis in an endemic areaClinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review.Buruli ulcer control in a highly endemic district in Ghana: role of community-based surveillance volunteers.Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients.Development of a dry-reagent-based qPCR to facilitate the diagnosis of Mycobacterium ulcerans infection in endemic countries.
P2860
Q21562264-56F6CFAC-5DDD-4278-B56B-FEFED0DCE55BQ24186073-EB2CD85F-8449-4383-80BD-5ADA8DB8D0ECQ28265322-78E96DE2-E768-4887-A12D-1058DD17DC99Q28267545-76A9C087-6A25-49B7-9D5C-096A730825A2Q28476689-EA7FDDB3-8847-4EDC-932B-3B5DA0931FEAQ28537749-2B6219BC-8A0F-4402-BAA0-9D30ECBFEE6EQ28538259-A1B567C2-0FAE-4E9F-A5EF-30291C01BF1FQ28543887-B715A988-328A-4554-AD3B-0D3AB380FED5Q30872520-33101704-536E-4D8D-9E2D-073A565E60EFQ30914398-BCF840F8-9671-4A72-AE1C-533AFA2AFE8AQ33324374-96DA6E12-9669-465C-85E8-91B731384730Q33325504-790DF4A0-7390-4FEF-89B7-9C7F39D5E59DQ33409842-947BDBBC-EEC2-4E7F-9BEB-F236A39CEA9DQ33631299-C381282F-56BD-47E8-9A0F-192ABE77B9BCQ33769921-D9F59A8F-E738-4EAA-9AA5-CE20C747A1D0Q33881961-F81725A8-615A-4282-9AD8-0E8CDD335DE8Q33909336-0D2AC5BC-7D7A-408C-8737-5263B035B7F0Q33962755-DC158F3F-84BB-4918-A205-3D0CC8740788Q33980134-A181DE44-9AC4-44D9-8FB2-074BFB9AD160Q33980141-B9CD2947-2562-4098-AD10-474FA30E4632Q33988898-70C0C5A0-6254-46B2-ACB2-79DEB38DAE4AQ33995558-DF834125-A65F-4D83-B497-39A94DA6604FQ34043539-342062AE-BA0B-45F6-A3A5-44405103FF50Q34108789-FD4976AE-1602-45EF-BA98-1614A7F47874Q34137837-D6BA8EF0-B58F-413E-8810-E23E5A7C1EE8Q34218700-5283D4C0-4311-469A-B116-1431911B11B0Q34235687-0E5545EE-736B-413C-8641-60ADFB35D817Q34281971-83D9DE94-119C-4039-A16C-922708A17765Q34483614-9E38DB52-96A8-4DEB-AB28-16B6963F40CBQ34484489-AC4BBE68-C5EA-4367-8698-8000EA412EC7Q34500901-99C9F880-8D4F-4656-85FF-DB61C1B24EEEQ34516081-D4937A3A-1FB1-4DF5-A687-D1574A3EB4E3Q34566628-68A67A0B-6A18-4EF7-B602-7C9968909AE4Q34954144-78D58812-A6C5-436A-B39D-F17FC5756F56Q35058098-0C9149F9-E3B1-400A-BE2E-68B630BACE57Q35083532-1E8D1D84-4F83-42AB-BCC8-F40DD2C3233BQ35084312-95951BD0-69BE-4151-BDC1-BA7CB89AC7DFQ35140526-4F5775B9-8EB2-4800-823C-CFD6DF9F7011Q35156761-E7917237-40D2-4AB3-9085-7A8A78F38F8CQ35241003-A0702873-6832-4B47-8410-A7062F6C6945
P2860
Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Promising clinical efficacy of ...... ycobacterium ulcerans disease)
@ast
Promising clinical efficacy of ...... ycobacterium ulcerans disease)
@en
type
label
Promising clinical efficacy of ...... ycobacterium ulcerans disease)
@ast
Promising clinical efficacy of ...... ycobacterium ulcerans disease)
@en
prefLabel
Promising clinical efficacy of ...... ycobacterium ulcerans disease)
@ast
Promising clinical efficacy of ...... ycobacterium ulcerans disease)
@en
P2093
P2860
P356
P1476
Promising clinical efficacy of ...... ycobacterium ulcerans disease)
@en
P2093
Ambroise Adeye
Annick Chauty
Augustin Guédénon
Christian Johnson
Eric Nuermberger
Hélène Euverte
Jacques Aubry
Jacques Grosset
Marie-Françoise Ardant
P2860
P304
P356
10.1128/AAC.00175-07
P407
P577
2007-05-25T00:00:00Z